Copenhagen, Denmark – March 2026 – The AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders concluded successfully after five days of scientific exchange and collaboration in Copenhagen. Held 17–21 March 2026 at the Bella Center Copenhagen and online, the hybrid event brought together more than 5,900 participants from over 70 countries, reaffirming its position as one of the leading global forums for advancing research into neurodegenerative diseases.
The AD/PD™ series of conferences continues to serve as a central meeting point for the international community working to understand and treat Alzheimer’s disease, Parkinson’s disease and related neurological disorders. By examining both the similarities and differences among these conditions, the conference provides a unique scientific platform focused on mechanisms of disease, prevention strategies and emerging therapeutic approaches.
A Global Platform for Scientific Discovery
AD/PD™ 2026 delivered an extensive scientific programme designed to showcase the latest developments in neurodegeneration research. Across the five-day meeting, participants engaged in:
• 109 scientific symposia
• 13 industry symposia
• 6 plenary lectures
• More than 730 on-site presentations
• Over 60 on-demand sessions
The conference also offered 38.5 CME-accredited educational hours, supporting continuing professional education for clinicians and researchers across the neurological sciences.
A key strength of the meeting lies in its multidisciplinary approach, bringing together clinical investigators, basic scientists and emerging researchers to foster collaboration across the full spectrum of neurodegenerative disease research. The International Scientific Advisory Board ensured a programme reflecting the breadth of expertise across Alzheimer’s disease, Parkinson’s disease and related disorders.
A Community Driving Rapid Progress
As research into neurodegenerative diseases accelerates, the AD/PD™ conference continues to reflect the growing momentum in the field. From novel therapeutic strategies to breakthroughs in biomarkers and disease mechanisms, many attendees highlighted the remarkable pace of innovation shaping the future of diagnosis and treatment.
Participants described the meeting as both scientifically stimulating and deeply collaborative.
Professor Henrik Zetterberg, University of Gothenburg, shared:
“A big THANK YOU for an amazing week in Copenhagen. I came home completely exhausted in a wonderful way, full of impressions. This meeting contained truly amazing and very thought-provoking presentations. To me, it felt like the best meeting on neurodegenerative diseases I have ever been to. It is clear to me that we have entered a new and very positive phase, and that the speed of discovery and progress is higher than ever with quite innovative approaches.”
Dr Marco Prado, University of Western Ontario, added:
“This was one of the most exciting meetings I have been in a long time. The programme was exceptional and so many advancements. I enjoyed enormously the fireside chat discussion and the different perspectives. Congratulations to you and the team for a perfect meeting.”
Reflecting on the growth of the field, Fiona Ducotterd, University College London, noted:
“The conference has grown so much, because the field has grown so much. The conference this year is one of the most exciting I’ve been to.”
Supporting the Next Generation of Researchers
A defining feature of the AD/PD™ conference is its commitment to fostering new talent. Through initiatives such as the Junior Faculty Awards, the meeting encourages participation from young scientists and early-career researchers, helping cultivate the next generation of leaders in neurodegenerative disease research.
Combined with an open and collegial atmosphere, these efforts create an environment that promotes scientific dialogue, networking and collaboration, enabling both established experts and emerging investigators to contribute to advancing the field.
From Vision to Global Scientific Exchange
The conference was organised with the support of Kenes Group, the leading global professional congress organiser specialising in medical and scientific events. Working closely with the conference leadership and scientific advisory board, Kenes Group delivered a highly complex hybrid meeting that enabled both in-person and virtual participants to engage with the latest research and connect with peers worldwide.
Looking Ahead
With its combination of cutting-edge science, interdisciplinary collaboration and strong global participation, AD/PD™ 2026 once again demonstrated why the conference remains a cornerstone event for the neurodegenerative disease community.
As discoveries continue to accelerate and new therapeutic strategies emerge, the AD/PD™ series of conferences will remain at the forefront of bringing researchers, clinicians and innovators together to drive progress towards improved understanding, prevention and treatment of Alzheimer’s, Parkinson’s and related disorders.
For more information, visit https://adpd.kenes.com/